Status:
COMPLETED
Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease
Lead Sponsor:
Hopital Foch
Collaborating Sponsors:
Hospital Ambroise Paré Paris
University Hospital, Brest
Conditions:
Pneumonia, Viral
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is complicated by pneumonia (15 to 20% of cases) requiring hospitalization with oxygen therapy. Almost 20 to 25% of ho...
Detailed Description
The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is complicated by pneumonia (15 to 20% of cases) requiring hospitalization with oxygen therapy. Almost 20 to 25% of ho...
Eligibility Criteria
Inclusion
- ≥ 18 years
- Any patient who consults in the emergency room, COVID+ with hospitalization criteria (dyspnea or desaturation ≤ 95% or chest pain or hemoptysis), including those who have already performed a CT angiogram upon arrival at the hospital.
- Positive polymerase chain reaction (PCR) of coronavirus disease or compatible clinical signs associated with suggestive radiological criteria
- Fever
- Cough
- Myalgia
- Asthenia
- Loss of taste/ Anosmia
- signed informed consent before any study procedure
- patients affiliated to an appropriate health insurance system
Exclusion
- Pregnancy in progress
- Patient not having a microbiological diagnosis of SARS Coronavirus (COV-2) infection or whose symptoms are not suggestive
- \< 18 years
- Be deprived of liberty or under guardianship
- Patient with contra-indication to thoracic angiography scanner:
- State of shock
- Creatinine clearance \< 30 mL/mn in Chronic Kidney Disease (CKD)
- history of anaphylactic shock or angioedema with iodinated contrast media
- uncontrolled cardiac decompensation
- Patient with contra-indication to contrast media (Iomeron350®, Visipaque®):
- History of immediate major or delayed skin reaction to the injection of a contrast medium
- Hypersensitivity to the active substance or to any of the excipients
- overt thyrotoxicosis
- Patients with renal insufficiency and / or patients with allergy to iodinated contrast products may be included if they can perform a scintigraphy (the pulmonary scintigraphy being the alternative diagnostic to the CT angiography for renal insufficiency and / or allergy to iodinated contrast products).
Key Trial Info
Start Date :
May 26 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 5 2022
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT04479540
Start Date
May 26 2020
End Date
March 5 2022
Last Update
August 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Foch
Suresnes, France, 92150